Company news

Neurogene Inc. news in 2025

Neurogene Inc.'s news releases, calls and decks from 2025, newest first.

View company

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 4, 2025

Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates

November 13, 2025

Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

November 12, 2025

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

November 6, 2025

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

October 9, 2025

Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

October 8, 2025

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

August 11, 2025

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

June 30, 2025

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

May 16, 2025

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

May 9, 2025

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

April 28, 2025

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

April 2, 2025

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

March 24, 2025

Neurogene to Participate in Upcoming Conferences

February 24, 2025

Decks in 2025